Cargando…

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants

Monovalent SARS-CoV-2 Prototype (Wuhan-Hu-1) and bivalent (Prototype + BA.4/5) COVID-19 vaccines have demonstrated a waning of vaccine-mediated immunity highlighted by lower neutralizing antibody responses against SARS-CoV-2 Omicron XBB sub-variants. The reduction of humoral immunity due to the rapi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Nita, Trost, Jessica F., Guebre-Xabier, Mimi, Zhou, Haixia, Norton, Jim, Jiang, Desheng, Cai, Zhaohui, Zhu, Mingzhu, Marchese, Anthony M., Greene, Ann M., Mallory, Raburn M., Kalkeri, Raj, Dubovsky, Filip, Smith, Gale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628164/ https://www.ncbi.nlm.nih.gov/pubmed/37932354 http://dx.doi.org/10.1038/s41598-023-46025-y

Ejemplares similares

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
por: Faraone, Julia N., et al.
Publicado: (2023)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2
por: Popovic, Marko E.
Publicado: (2023)

What to know about Omicron XBB.1.5
por: Vogel, Lauren
Publicado: (2023)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

XBB.1.5 emerges in the Americas: what it means to the region
por: Hotez, Peter
Publicado: (2023)

Another variant, XBB.1.5: will it be a tsunami for the Americas?
por: The Lancet Regional Health – Americas
Publicado: (2023)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

Imprinted hybrid immunity against XBB reinfection
por: Boyton, Rosemary J, et al.
Publicado: (2023)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Distinctive Features of the XBB.1.5 and XBB.1.16 Spike Protein Receptor-Binding Domains and Their Roles in Conformational Changes and Angiotensin-Converting Enzyme 2 Binding
por: Sharma, Tej, et al.
Publicado: (2023)

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
por: Yue, Can, et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Recent update on XBB.1.5 emerging novel mutation of COVID-19
por: Amin, Ruhul, et al.
Publicado: (2023)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
por: He, Cai, et al.
Publicado: (2023)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Molecular In-Depth on the Epidemiological Expansion of SARS-CoV-2 XBB.1.5
por: Scarpa, Fabio, et al.
Publicado: (2023)

Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis
por: Klein, Eili Y., et al.
Publicado: (2023)

Mass-decorrelated Xbb Tagger using Adversarial Neural Network
por: Chen, Shihlung
Publicado: (2022)

Long COVID-19 syndrome associated with Omicron XBB.1.5 infection: a case report
por: Espíndola, Otávio, et al.
Publicado: (2023)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023)

Adaptability of single nucleotide polymorphism (SNP)-PCR for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1
por: Ritchie, Gordon, et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
por: Affeldt, Patrick, et al.
Publicado: (2023)

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
por: Entzminger, Kevin C, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s5bljjd32gjq1a974sod1ck45g